story of the week
Pembrolizumab Plus Ipilimumab After Anti–PD-1/L1 Failure for Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma
J. Clin. Oncol 2021 May 04;[EPub Ahead of Print], DJ Olson, Z Eroglu, B Brockstein, AS Poklepovic, M Bajaj, S Babu, S Hallmeyer, M Velasco, J Lutzky, E Higgs, R Bao, TC Carll, B Labadie, T Krausz, Y Zha, T Karrison, VK Sondak, TF Gajewski, NI Khushalani, JJ LukeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.